Metastatic lung adenocarcinoma related alpha-Fetoprotein elevation in a patient with HBV-related cirrhosis

Hamamci M., Karaahmet F., Akinci H., Kilincalp S., Acikgoz R., Coban S., ...More

ACTA GASTRO-ENTEROLOGICA BELGICA, vol.78, no.4, pp.441-442, 2015 (SCI-Expanded) identifier identifier

  • Publication Type: Article / Letter
  • Volume: 78 Issue: 4
  • Publication Date: 2015
  • Journal Name: ACTA GASTRO-ENTEROLOGICA BELGICA
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, EMBASE, MEDLINE
  • Page Numbers: pp.441-442
  • Ankara Yıldırım Beyazıt University Affiliated: Yes

Abstract

HCC is the most common type of primary liver tumor. The Practice Guideline, AASLD, for HCC recommended surveillance of HBV carriers at high risk of HCC with US every 6-12 months. Laboratory surveillance option is the measurement of serum alpha-fetoprotein level which has long been used for the diagnosis of HCC. But, increased serum levels of alpha-fetoprotein are also seen in acute hepatitis, cirrhosis, and malignancies include yolk sac carcinoma, neuroblastoma, hepatoblastoma, gastric and lung carcinoma. Because of elevation alpha-fetoprotein in these malignancies, liver mass with an elevated alpha-fetoprotein does not directly indicate HCC. For these reason, clinicians evaluating patient with liver mass and HBV-related cirrhosis should be vigilant for other case of alpha-fetoprotein elevation.